Late in 2015, a global pharmaceutical company was, for the first time, beginning to suffer from an increasingly competitive landscape ...

A leading global pharmaceutical company needed to rethink how it approached the ongoing digital revolution. With over $50 billion in annual ...

Life sciences companies will need to reevaluate their marketing approach as off-label and direct-to-customer (DTC) marketing continue to draw attention. In recent ...

As large pharmaceutical companies increase their focus on orphan and specialty drugs, they are also seeking ways to reduce operating expenses and ...

In a letter this week to its suppliers, McKesson—the largest pharmaceutical distributor in the United States—addressed their expectations relating to ...

While increased healthcare spend will likely lead to higher revenues for manufacturers, life sciences companies will focus heavily on addressing ...

Launching a new, undifferentiated drug in a mature and highly regulated market can be challenging—even for an established organization. Facing the ...

The leadership team of a multinational healthcare company was dissatisfied with the organization’s ability to realize true value from its large scale. ...

As pharmaceutical companies introduce new therapies to the U.S. market, they respond to risk-sharing agreements (RSAs) from healthcare providers, which ...

Developing data strategies for the storage, analysis and protection of patient-specific data has never been more critical to the future ...

Many nations have enacted serialization regulations to combat counterfeit products and diversions of legitimate pharmaceutical products, and those that have not are planning ...

The global regulatory landscape is continuously evolving to protect patients and ensure supply chain visibility. Companies will need flexible implementation plans and increasingly agile ...